© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Ian Ingram
Articles
FDA Approves Abiraterone/Prednisone for Metastatic Prostate Cancer
February 08, 2018
The US Food and Drug Administration has approved abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic prostate cancer patients with high-risk, castration-sensitive disease.
FDA Expands Approval of EGFR Inhibitor for Lung Cancer Treatment
January 17, 2018
The FDA has expanded the approval of afatinib (Gilotrif) to include the first-line treatment of metastatic non–small-cell lung cancer patients whose tumors have non-resistant EGFR mutations, including three newly identified substitution mutations.
FDA Approves First Drug for BRCA-Positive Breast Cancer
January 12, 2018
The FDA has expanded the approval of the PARP inhibitor olaparib (Lynparza) to include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.
FDA Approves Brentuximab Vedotin for Cutaneous Lymphoma
November 10, 2017
The FDA has approved brentuximab vedotin (Adcetris) for the treatment of primary cutaneous anaplastic large-cell lymphoma and CD30-expressing mycosis fungoides in patients who have received prior systemic therapy.